SCHEMBL4293517

SCHEMBL4293517

CCC(C)CCCCCOC(=O)CCc1ccc(O)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.55
CYP2C9 P11712 6/20 0.55
CYP2C19 P33261 6/20 0.55
HTR1A P08908 6/20 0.55
CYP2C8 P10632 5/20 0.55
CYP2B6 P20813 5/20 0.55
CYP1A2 P05177 5/20 0.55
CYP2D6 P10635 4/20 0.55
CYP2A6 P11509 3/20 0.55
LTA4H P09960 3/20 0.55
CYP2E1 P05181 2/20 0.55
TRPV1 Q8NER1 3/20 0.53
ALOX5 P09917 2/20 0.51
OR51E2 Q9H255 1/20 0.51
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
TSHR P16473 1/20 0.49
BLM P54132 1/20 0.49
PMP22 Q01453 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286230 1.00 CYP3A4 (0.55) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL4288689 0.90 CYP3A4 (0.60) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL4283544 0.90 CYP3A4 (0.60) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL4288845 0.90 CYP3A4 (0.60) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL4281842 0.89 CYP3A4 (0.58) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL16661624 0.87 ALOX5 (0.65) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL21034088 0.86 CYP3A4 (0.71) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL16661623 0.85 ALOX5 (0.65) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL3340655 0.84 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8
SCHEMBL3337181 0.84 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19HTR1ACYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765809-B2 Ester derivative and use thereof AJINOMOTO CO., INC. (JP) 2014-07-01 US disclosed
US-20130053441-A1 NOVEL ESTER DERIVATIVE AND USE THEREOF AJINOMOTO CO., INC. (JP) 2013-02-28 US disclosed
US-8212068-B2 Ester derivative and use thereof AJINOMOTO CO., INC. (JP) 2012-07-03 US disclosed
US-20090170942-A1 ESTER DERIVATIVE AND USE THEREOF AJINOMOTO CO. INC (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053441-A1 NOVEL ESTER DERIVATIVE AND USE THEREOF MEP1A, CES2, MEP1B CYP3A4 472/4885CYP2C9 645/4885CYP2C19 178/4885
US-20090170942-A1 ESTER DERIVATIVE AND USE THEREOF MEP1A, CES2, F8 CYP3A4 502/4885CYP2C9 568/4885CYP2C19 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.